Akèy › Kansè nan tete › Alabama › Birmingham
Etid klinik pou Kansè nan tete nan Birmingham, AL
24 etid pou Kansè nan tete ap chèche patisipan nan sit nan ak bò kote Birmingham (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →
A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
Ap rekriteFaz 2
- UAB O'Neal Comprehensive Cancer Center - The Kirklin Clinic of UAB Hospital, Birmingham
Phase IIIb Study of Ribociclib + ET in Early Breast Cancer
Ap rekriteFaz 3
- Central Alabama Research, Birmingham
A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer
Ap rekriteFaz 2
- Alabama Oncology, Birmingham
PRE-ISPY Phase I/II Oncology Platform Program
Ap rekriteFaz 1/2
- The University of Alabama at Birmingham O'Neal Comprehensive Cancer Center, Birmingham
Phase II Single Arm Trial of Low Dose Capecitabine in Patients With Advanced Breast Cancer
Ap rekriteFaz 2
- University of Alabama at Birmingham, Birmingham
An Investigational Study of BG-75202 Alone and in Combination With Other Therapeutic Agents in Adults With Advanced Solid Tumors
Ap rekriteFaz 1
- University of Alabama At Birmingham Hospital, Birmingham
Improved Successful Retrieval Rate of HydroMARK Plus Breast Biopsy Site Marker in Comparison to HydroMARK as Well as Improved Surgeon Satisfaction
Ap rekrite
- The Kirklin Clinic, Birmingham
A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors
Ap rekriteFaz 1/2
- University of Alabama at Birmingham, Birmingham
A Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Early Breast Cancer
Ap rekriteFaz 2
- University of Alabama at Birmingham, Birmingham
Women Informed to Screen Depending on Measures of Risk (Wisdom Study)
Ap rekriteVolontè an sante akeyi
- University of Alabama at Birmingham, Birmingham
Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
Ap rekriteFaz 1
- University of Alabama Birmingham, Birmingham
Evaluating Minimal Residual Disease (MRD) Through Longitudinal Circulating Tumor DNA (ctDNA) Profiling in Breast Malignancies
Ap rekriteEtid obsèvasyon
- Birmingham Hematology Associates, Birmingham
TReatment of ADC-Refractory Breast CancEr With Dato-DXd or T-DXd: TRADE DXd
Ap rekriteFaz 2
- University of Alabama, Birmingham
Comparison of Breast Cancer Screening With CESM to DBT in Women With Dense Breasts
Ap rekriteVolontè an sante akeyi
- University of Alabama, Birmingham, Birmingham
Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers
Ap rekriteFaz 1
- Uni of Alabama at Birmingham, Birmingham
Promoting Resilience in Women With Breast Cancer (PRISM -MBC)
Ap rekrite
- The University of Alabama, Birmingham
I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
Ap rekriteFaz 2
- University of Alabama at Birmingham, Birmingham
Comparative Effectiveness Trial of Two Supportive Cancer Care Delivery Models for Adults With Cancer
Ap rekrite
- University of Alabama at Birmingham, Birmingham
A Study of Enzalutamide, Enzalutamide in Combination With Mifepristone, or Chemotherapy in People With Metastatic Breast Cancer
Ap rekriteFaz 2
- University of Alabama at Birmingham, Birmingham
Positron Emission Tomography (PET) Imaging With Zirconium-89 (89Zr)-Trastuzumab for Prediction of HER2 Targeted Therapy Effectiveness
Ap rekriteFaz 1 bonè
- The Kirklin Clinic, Birmingham
Gene Signatures to Guide HR+MBC Therapy in a Diverse Cohort
Ap rekriteFaz 2
- University of Alabama Birmingham, Birmingham
Time-Restricted Eating and Cancer: Clinical Outcomes, Mechanisms, and Moderators
Ap rekrite
- The University of Alabama at Birmingham, Birmingham
RAD 1802: Pilot Trial of Five Fraction Stereotactic Body Radiotherapy for Early Stage Breast Cancer Patients Eligible for Post-Operative Accelerated Partial Breast Irradiation (APBI)
Ap rekrite
- University of Alabama at Birmingham (UAB) Hazelrig-Salter Radiation Oncology Center (HSROC), Birmingham
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Ap rekriteEtid obsèvasyon
- Massive Bio SYNERGY-AI site, Birmingham
Etid Kansè nan tete nan lòt vil
- New York City, NY136 etid
- Houston, TX126 etid
- Boston, MA112 etid
- Nashville, TN81 etid
- Los Angeles, CA73 etid
- Edison, NJ68 etid
- St. Louis, MO64 etid
- Queens, NY64 etid
- Durham, NC64 etid
- Chicago, IL59 etid
- Philadelphia, PA56 etid
- Dallas, TX55 etid
Lòt etid nan Birmingham
- Kansè (tout kalite)31 etid
- Kansè ovè23 etid
- Obèsite23 etid
- Kansè Poumon ki pa ti selil22 etid
- Leksemi mieloïd egi21 etid
- Myelom Miltip18 etid
- BPCO17 etid
- Maladi kadyovaskilè17 etid
- Dyabèt Tip 216 etid
- Kansè Endomèt16 etid
- Sipwa16 etid
- Fibroz sistik16 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 6, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.